Daniel Christ

General Information

Experience

Founder and Chief Scientific Officer  - Solvanix Pty Ltd

Education

Ph.D.  - Garvan Institute of Medical Research

Affiliations

Founder and Chief Scientific Officer  - Solvanix Pty Ltd

Scientific Advisory Board Member  - PEGS

Fellow  - Trinity College

Recent News  

Associate Professor Daniel Christ
Founder and Chief Scientific Officer Daniel is the Founder and Chief Scientific Officer of Solvanix. He presently heads the Antibody Therapeutics Laboratory at the Garvan Institute of Medical Research in Sydney and holds a conjoint appointment as Associate Professor of Medicine at UNSW Australia.

Read More

Associate Professor Daniel Christ
Founder and Chief Scientific Officer Daniel is the Founder and Chief Scientific Officer of Solvanix. He presently heads the Antibody Therapeutics Laboratory at the Garvan Institute of Medical Research in Sydney and holds a conjoint appointment as Associate Professor of Medicine at UNSW Australia. His research at the Garvan focuses on the engineering of antibodies and cytokines for medical applications. At Cambridge, Christ and Winter further developed monoclonal antibody technology, particularly in the field of domain antibodies (commercialised through Domantis Ltd - sold to GSK for £230 million in 2006). Dr Christ's work has attracted in excess of $5 million of compeptitive research funding and numerous awards, including a fellowship of Trinity College (Cambridge University) and an NHMRC excellence award.

Read More

Associate Professor Daniel Christ
Founder and Chief Scientific Officer Daniel is the Founder and Chief Scientific Officer of Solvanix. He presently heads the Antibody Therapeutics Laboratory at the Garvan Institute of Medical Research in Sydney and holds a conjoint appointment as Associate Professor of Medicine at UNSW Australia. His research at the Garvan focuses on the engineering of antibodies and cytokines for medical applications. At Cambridge, Christ and Winter further developed monoclonal antibody technology, particularly in the field of domain antibodies (commercialised through Domantis Ltd - sold to GSK for £230 million in 2006). Dr Christ's work has attracted in excess of $5 million of compeptitive research funding and numerous awards, including a fellowship of Trinity College (Cambridge University) and an NHMRC excellence award.

Read More

Browse ZoomInfo’s Directories